Crizotinib (DrugBank: Crizotinib)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04283669 (ClinicalTrials.gov) | February 18, 2020 | 22/2/2020 | Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas | Neurofibromatosis 2;Progressive Vestibular Schwannoma (VS) | Drug: Crizotinib | University of Alabama at Birmingham | Memorial Sloan Kettering Cancer Center | Recruiting | 6 Years | N/A | All | 19 | Phase 2 | United States |